Home › Leiomyosarcoma › Texas
Leiomyosarcoma clinical trials in Texas
7 studies for Leiomyosarcoma are looking for participants at sites in Texas.
Cities in Texas
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
- UT MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06498648Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- M D Anderson Cancer Center, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT04031677Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
- UT MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT05711615STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
- NEXT Dallas, Irving
- and 2 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT06975293A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07633756Metastatic Leiomyosarcoma Biomarker Protocol
- MD Anderson, Houston
RecruitingObservational study
All ages · All sexes · Updated Jun 24, 2026 · NCT05653388A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT06789172From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.